Intravitreal bevacizumab (Avastin) for post laser anterior segment ischemia in aggressive posterior retinopathy of prematurity

Indian J Ophthalmol. 2007 Jan-Feb;55(1):75-6. doi: 10.4103/0301-4738.29505.

Abstract

Aggressive posterior retinopathy of prematurity (formerly known as fulminate/type II/rush disease) occurs in zone 1 or posterior zone 2. Treatment involves extensive near confluent laser ablation of a large area of avascular retina. Anterior segment ischemia is a rare complication that can occur due to injury to the long posterior ciliary arteries in the horizontal meridians during aggressive posterior laser treatment. The outcome of this rare complication is very poor. This case describes a favorable outcome of intravitreal injection of bevacizumab (Avastin) in a case of anterior segment ischemia.

Publication types

  • Case Reports

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use*
  • Anterior Eye Segment / blood supply*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab
  • Humans
  • Infant, Newborn
  • Ischemia / drug therapy*
  • Ischemia / etiology
  • Laser Therapy / adverse effects*
  • Male
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / etiology
  • Retinopathy of Prematurity / physiopathology
  • Retinopathy of Prematurity / surgery*
  • Severity of Illness Index

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab